Prescient Therapeutics is planning a clinical trial of PTX-100 in RhoA-mutant lymphomas, a niche indication where the company could potentially conduct a pivotal study before out-licensing. It has resumed recruitment in the Phase Ib component of trials of lead anti-cancer compound PTX-200 in acute myeloid leukaemia (AML) and ovarian cancer, and is working with the FDA to recommence its Phase II breast cancer study. The company had A$6.9m cash on 30 September, sufficient to fund operations int
20 Nov 2017
PTX-100 to target RhoA-mutant lymphomas
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
PTX-100 to target RhoA-mutant lymphomas
Prescient Therapeutics Limited (PTX:ASX) | 0 0 0.0%
- Published:
20 Nov 2017 -
Author:
Dr Dennis Hulme -
Pages:
9
Prescient Therapeutics is planning a clinical trial of PTX-100 in RhoA-mutant lymphomas, a niche indication where the company could potentially conduct a pivotal study before out-licensing. It has resumed recruitment in the Phase Ib component of trials of lead anti-cancer compound PTX-200 in acute myeloid leukaemia (AML) and ovarian cancer, and is working with the FDA to recommence its Phase II breast cancer study. The company had A$6.9m cash on 30 September, sufficient to fund operations int